Table 2.
Baseline characteristics of patients who received adjuvant FOLFOX
| Adjuvant chemotherapy (n = 65) | Perioperative chemotherapy (n = 100) | P ‡ | |
|---|---|---|---|
| Age (years)* | 63·6 (25·0–80·6) | 60·9 (32·2–88·6) | 0·321§ |
| Sex ratio (M : F) | 47 : 18 | 62 : 38 | 0·231 |
| Primary tumour | |||
| Location | 0·075 | ||
| Right transverse colon | 13 of 64 (20) | 30 of 98 (31) | |
| Left colon | 36 of 64 (56) | 57 of 98 (58) | |
| Rectum | 15 of 64 (23) | 11 of 98 (11) | |
| Stage T3–4 | 32 (49) | 86 of 94 (91) | < 0·001 |
| Node‐positive | 43 (66) | 65 (65) | > 0·999 |
| Disease history | < 0·001 | ||
| Synchronous | 32 (49) | 77 (77) | |
| Metachronous without previous chemotherapy | 13 (20) | 4 (4) | |
| Metachronous with previous chemotherapy | 20 (31) | 19 (19) | |
| Hepatic disease | |||
| Maximum tumour size (mm)* | 25 (3–100) | 30 (1–100) | 0·042§ |
| No. of tumours* | 1 (1–5) | 2 (1–5) | 0·009§ |
| CEA level > 5 ng/ml at diagnosis | 17 (26) | 30 (30) | 0·720 |
| Surgical procedures and outcomes | |||
| Order of resections | 0·239 | ||
| Primary tumour resection first | 43 (66) | 77 (77) | |
| Simultaneous liver and primary resection | 21 (32) | 21 (21) | |
| Liver first | 1 (2) | 2 (2) | |
| Major hepatectomy (≥ 3 segments) | 7 (11) | 25 (25) | 0·040 |
| Dindo–Clavien grade ≥ III | 6 (9) | 9 (9) | > 0·999 |
| Positive resection margins | 8 of 63 (13) | 33 of 96 (34) | 0·004 |
| Adjuvant chemotherapy | |||
| Postoperative bevacizumab or cetuximab | 3 (5) | 18 (18) | 0·023 |
| Tumour genotype | |||
| KRAS/BRAF mutation† | 14 of 31 (45) | 21 of 53 (40) | 0·789 |
Values in parentheses are percentages unless indicated otherwise;
*
values are median (range).
†
KRAS exons 2 and 3, and BRAF exon 15. CEA, carcinoembryonic antigen.
‡
χ2 or Fisher's exact test, except
§
Wilcoxon signed rank test.